[go: up one dir, main page]

AU2001249737A1 - Antibody antagonists of ve-cadherin without adverse effects on vascular permeability - Google Patents

Antibody antagonists of ve-cadherin without adverse effects on vascular permeability

Info

Publication number
AU2001249737A1
AU2001249737A1 AU2001249737A AU4973701A AU2001249737A1 AU 2001249737 A1 AU2001249737 A1 AU 2001249737A1 AU 2001249737 A AU2001249737 A AU 2001249737A AU 4973701 A AU4973701 A AU 4973701A AU 2001249737 A1 AU2001249737 A1 AU 2001249737A1
Authority
AU
Australia
Prior art keywords
cadherin
human
antibody
adverse effects
vascular permeability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001249737A
Inventor
Peter Bohlen
Daniel J. Hicklin
Fang Liao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ImClone LLC
Original Assignee
ImClone Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ImClone Systems Inc filed Critical ImClone Systems Inc
Publication of AU2001249737A1 publication Critical patent/AU2001249737A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The murine epitope sequence recognized by antibody E4B9 shares 100% homology with human VE-cadherin, so this antibody was examined to determine if it cross-reacts with human VE-cadherin. Western-blot analysis of several VE-cadherin expressing human and murine cells indicated that E4B9 indeed cross-reacts with human VE-cadherin (FIG. 6). This finding facilitates development of a "humanized" E4B9 antibody and its success in the preclinical development since its anti-tumor activity can be tested extensively in several mouse models.
AU2001249737A 2000-03-31 2001-03-30 Antibody antagonists of ve-cadherin without adverse effects on vascular permeability Abandoned AU2001249737A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54096700A 2000-03-31 2000-03-31
US09540967 2000-03-31
PCT/US2001/010505 WO2001075109A2 (en) 2000-03-31 2001-03-30 Antagonist antibodies to ve-cadherin without adverse effects on vascular permeability

Publications (1)

Publication Number Publication Date
AU2001249737A1 true AU2001249737A1 (en) 2001-10-15

Family

ID=24157649

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001249737A Abandoned AU2001249737A1 (en) 2000-03-31 2001-03-30 Antibody antagonists of ve-cadherin without adverse effects on vascular permeability

Country Status (12)

Country Link
US (4) US7371574B2 (en)
EP (1) EP1268799B1 (en)
JP (1) JP2003529370A (en)
AT (1) ATE425255T1 (en)
AU (1) AU2001249737A1 (en)
CA (1) CA2404576A1 (en)
CY (1) CY1109097T1 (en)
DE (1) DE60137915D1 (en)
DK (1) DK1268799T3 (en)
ES (1) ES2323938T3 (en)
PT (1) PT1268799E (en)
WO (1) WO2001075109A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7481999B2 (en) 1998-05-05 2009-01-27 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin-mediated function
CA2506037A1 (en) 2002-11-14 2004-06-10 Adherex Technologies, Inc. Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion
JP2004175689A (en) * 2002-11-25 2004-06-24 Kureha Chem Ind Co Ltd Agent for inhibiting tumor metastasis
US20040167076A1 (en) 2003-02-14 2004-08-26 Stamer W. Daniel Modulation of aqueous humor outflow by targeting vascular-endothelial-cadherin in schlemm's canal cells
GB0602063D0 (en) 2006-02-02 2006-03-15 Univ Manchester Cell Culture
US9207242B2 (en) * 2008-10-09 2015-12-08 The University Of Hong Kong Cadherin-17 as diagnostic marker and therapeutic target for liver cancer
WO2011071541A2 (en) * 2009-12-11 2011-06-16 The Scripps Research Institute Cadherin modulatory agents

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5036003A (en) * 1987-08-21 1991-07-30 Monsanto Company Antibodies to VPF
WO1993008210A1 (en) * 1991-10-18 1993-04-29 Beth Israel Hospital Association Vascular permeability factor targeted compounds
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
DE69332948T2 (en) * 1992-03-05 2003-11-27 Board Of Regents, The University Of Texas System Use of immunoconjugates for the diagnosis and / or therapy of vascularized tumors
US5646250A (en) * 1992-04-17 1997-07-08 Doheny Eye Institute Cadherin polypeptides
CA2111573C (en) * 1992-04-17 2002-11-26 Shintaro Suzuki Cadherin materials and methods
US5597725A (en) * 1992-04-17 1997-01-28 Doheny Eye Institute Cadherin-specific antibodies and hybridoma cell lines
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US5861499A (en) * 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US5730977A (en) * 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
US20050222037A1 (en) * 1998-05-05 2005-10-06 Adherex Technologies, Inc. Compounds and methods for modulating VE-cadherin-mediated function
WO1999057149A2 (en) * 1998-05-05 1999-11-11 Adherex Technologies, Inc. Compounds and methods for modulating nonclassical cadherin-mediated functions
US20030206902A1 (en) * 2001-03-05 2003-11-06 Fang Liao Ve-cadherin and vegfr-2 antagonists for therapeutic modulation of angiogenesis

Also Published As

Publication number Publication date
US7371574B2 (en) 2008-05-13
JP2003529370A (en) 2003-10-07
ATE425255T1 (en) 2009-03-15
CY1109097T1 (en) 2014-07-02
EP1268799B1 (en) 2009-03-11
EP1268799A2 (en) 2003-01-02
DK1268799T3 (en) 2009-07-06
ES2323938T3 (en) 2009-07-28
US20080317750A1 (en) 2008-12-25
CA2404576A1 (en) 2001-10-11
PT1268799E (en) 2009-05-11
US20020160003A1 (en) 2002-10-31
WO2001075109A2 (en) 2001-10-11
DE60137915D1 (en) 2009-04-23
WO2001075109A3 (en) 2002-05-16
US20080311121A1 (en) 2008-12-18
US20090060909A1 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
CY1109097T1 (en) VE-CANADIN ANTIBODIES COMPETITORS WITHOUT NEGATIVE EFFECTS ON VASCULAR TRANSFER
AU2555297A (en) Monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen
IL138497A0 (en) Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
PH12022551650A1 (en) Anti-trem2 antibodies and methods of use thereof
DK0528767T3 (en) antibody derivatives
ATE158415T1 (en) CATIONIZED ANTIBODIES AGAINST INTRACELLULAR PROTEINS
ES2082775T3 (en) ANTIBODIES OF LATENT HUMAN PAPILOMAVIRUS PROTEINS, DIAGNOSTIC SYSTEMS AND PROCEDURES.
DK0528931T3 (en) Humanized chimeric anti-ICAM-1 antibodies, methods for their preparation and their use
FI854187A0 (en) IMMUNOANALYZER FOER DENATURERADE PROTEINANALYSER, SAERSKILT HB ALC, SAMT ANTIKROPPAR ANVAENDBARA I DESSA.
AU5505198A (en) Methods for diagnosis of allergic bronchopulmonary aspergillosis
ATE226247T1 (en) HUMAN NEURONAL NICOTINE-ACETYLCHOLINE RECEPTOR COMPOUNDS AND METHODS OF THEIR USE
WO2005103698A3 (en) Methods and antibodies for nitrofuran detection
IT1257893B (en) MONOCLONAL ANTIBODIES THAT RECOGNIZE AN EPITOPE OF HUMAN P-GLYCOPROTEIN.
AU2002314483A1 (en) System and method for analysis of a tissue
DE69529744D1 (en) MONOCLONAL ANTIBODIES SPECIFIC TO VASCULAR ENDOTHELCELL-LIKE ENDOGLYX-1, THE ANTIQUE SELF AND ITS USE
AU4661293A (en) Peptides representing antigenic epitopes of ige present on b cell but not basophil surface
ATE230761T1 (en) MONOCLONAL ANTIBODIES AGAINST A COMPLEX OF HUMAN ACT AND A SERINE PROTEASE
IT8021411A0 (en) SYNTHETIC POLYPEPTIDE ACTIVE AS AN ANTIGEN, AND PROCEDURE FOR ITS PREPARATION.
EP0563244A4 (en) Human phospholipase activating protein and methods for diagnosis of rheumatoid arthritis
ITRM930818A0 (en) PROCEDURE FOR THE PRODUCTION IN PLANTS OF ENGINEERED ANTIBODY, PRODUCED ANTIBODY AND THEIR USE IN DIAGNOSIS AND THERAPY.
IL96369A0 (en) Decapeptide,monoclonal antibodies directed thereto and their use in diagnosis
DK329789A (en) MONOCLONAL ANTIBODY
Rich Pride of the Ndebele
DE69111429D1 (en) MONOCLONAL ANTIBODIES THAT MAKE A DIFFERENCE BETWEEN NATIVE PROTEINS AND PROTEINS WITH A MODIFIED SEQUENCE.
Adams THE INFLUENCE OF COUNSELOR RACE, ATTIRE, AND SPEECH STYLE ON BLACK JUVENILE DELINQUENTS'PERCEPTION OF COUNSELOR ATTRACTIVENESS AND ABILITY TO BE WARM, EMPATHIC, AND GENUINE.